What does this drug actually do? And what did the clinical trial data show that convinced the FDA that it should be approved?

Thank you for that question.

Let me go a step back, though, because the difference in the last 20 years has been other clinical trials looking at other potential options for the treatment of bronchiectasis.

Although Brenzacatab is the first FDA-approved agent, and I'll talk to you more about that in a little bit, there have been a number of studies looking at inhaled antibiotics, including tobramycin, including colistin, and, of course, low-dose chronic azithromycin therapy has been studied and several studies published.

So we have some...

We had some treatment options available for our patients, including airway clearance.

And then for patients with a recurrent Higgs exacerbation, certainly we consider and used inhaled antibiotics and azithromycin.

How should clinicians think about patient selection or birth academy? Who's the ideal candidate for this therapy? Where do we still have gaps that we should be looking and identifying and filling?